Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study).
Vergnenègre A, Tillon J, Corre R, Barlési F, Berard H, Vernejoux JM, Le Caer H, Fournel P, Marin B, Chouaïd C. Vergnenègre A, et al. Among authors: chouaid c. J Thorac Oncol. 2009 Mar;4(3):364-70. doi: 10.1097/JTO.0b013e318197f4ff. J Thorac Oncol. 2009. PMID: 19155999 Free article. Clinical Trial.
Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease.
Savale L, Chaouat A, Bastuji-Garin S, Marcos E, Boyer L, Maitre B, Sarni M, Housset B, Weitzenblum E, Matrat M, Le Corvoisier P, Rideau D, Boczkowski J, Dubois-Randé JL, Chouaid C, Adnot S. Savale L, et al. Among authors: chouaid c. Am J Respir Crit Care Med. 2009 Apr 1;179(7):566-71. doi: 10.1164/rccm.200809-1398OC. Epub 2009 Jan 29. Am J Respir Crit Care Med. 2009. PMID: 19179485 Free PMC article.
Economics of treatments for non-small cell lung cancer.
Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Chouaid C, et al. Pharmacoeconomics. 2009;27(2):113-25. doi: 10.2165/00019053-200927020-00003. Pharmacoeconomics. 2009. PMID: 19254045 Review.
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C; 0506 GFPC Team. Vergnenegre A, et al. Among authors: chouaid c. J Thorac Oncol. 2011 Jan;6(1):161-8. doi: 10.1097/JTO.0b013e318200f4c1. J Thorac Oncol. 2011. PMID: 21150465 Free article. Clinical Trial.
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeño J, de Marinis F, Grossi F, Vergnenègre A, Walzer S. Banz K, et al. Among authors: chouaid c. Lung Cancer. 2011 Dec;74(3):529-34. doi: 10.1016/j.lungcan.2011.04.010. Epub 2011 May 17. Lung Cancer. 2011. PMID: 21592611
405 results